While revenue and cash (due to a high interest loan) are increasing, EPS will be decreasing, and that’s where investors need to be paying more attention. The delay and the loan do no favors for EPS, an arguably key metric when valuing a company. Melody would agree here, I think, considering his past arguments about EPS guidance failures by CEO.
Ann: AVITA Medical Q3 Revenue & Secures $90M Non-Dilutive Debt, page-30
-
- There are more pages in this discussion • 90 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add AVH (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$2.80 |
Change
0.120(4.48%) |
Mkt cap ! $193.9M | |||
| Open | High | Low | Value | Volume |
| $2.78 | $2.86 | $2.77 | $457.2K | 163.3K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 4531 | $2.80 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $2.83 | 2500 | 1 |
View Market Depth
| Last trade - 16.10pm 16/08/2024 (20 minute delay) ? |
| AVH (ASX) Chart |